BRAF p.V600E免疫组化在甲状腺癌FNA涂片与细胞块中的应用价值
本研究选取50例已知BRAF p.V600E突变状态的甲状腺癌FNA样本,在涂片和细胞块切片上进行VE1克隆抗体免疫染色,并与分子检测和/或手术标本免疫染色结果比较。细胞块免疫染色灵敏度和特异度分别为94.4%和100%,涂片为80%和63.6%。结论认为细胞块可可靠用于BRAF p.V600E免疫染色,但涂片假阳性限制其应用需谨慎解读。
要点
- 甲状腺癌FNA细胞块行BRAF p.V600E免疫染色灵敏度和特异度分别为94.4%和100%。
- FNA直接涂片BRAF p.V600E免疫染色灵敏度和特异度分别为80%和63.6%。
- 涂片假阳性结果限制其临床应用,需谨慎解读。
核心结论
- BRAF p.V600E免疫染色可可靠用于甲状腺FNA细胞块制备。
- 直接涂片上的假阳性结果限制其应用,需谨慎解读。
研究设计与样本
- 选取50例甲状腺癌FNA样本,包括乳头状癌29例、低分化癌10例、未分化癌9例和Hurthle细胞癌2例,均已知BRAF p.V600E突变状态。
- 使用抗BRAF p.V600E抗体(克隆VE1)在涂片和细胞块切片上进行免疫染色,并与同一患者分子检测和/或手术病理材料免疫染色结果比较。
主要发现
- 50例中26例有涂片可评估,阳性16例、阴性4例、可疑6例。
- 34例有细胞块可评估,阳性17例、阴性16例、可疑1例。
- 细胞块免疫染色总体灵敏度和特异度分别为94.4%和100%。
- 涂片免疫染色灵敏度和特异度分别为80%和63.6%。
关键数值与推荐
- 细胞块BRAF p.V600E免疫染色灵敏度94.4%、特异度100%。
- 涂片BRAF p.V600E免疫染色灵敏度80%、特异度63.6%。
临床怎么用
- 甲状腺FNA样本可优先采用细胞块行BRAF p.V600E免疫染色辅助快速分诊。
- 直接涂片免疫染色结果需谨慎解读,假阳性可能影响治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The identification of BRAF mutations in thyroid cancer has prognostic and therapeutic implications. Although the gold standard for identifying BRAF mutations is molecular testing, the ability to perform BRAF p.V600E immunostaining on fine-needle aspiration (FNA) samples can facilitate the rapid triaging of patients to treatment options. METHODS: A total of 50 thyroid carcinoma FNA samples, including papillary (29 samples), poorly differentiated (10 samples), anaplastic (9 samples), and Hurthle cell (2 samples) carcinomas, with a known BRAF p.V600E mutation status were selected for the current study. Immunostaining was performed on smears and cell block sections using an anti-BRAF p.V600E antibody (clone VE1). The results were compared with the known mutation status obtained by molecular testing and/or immunostaining of surgical pathology material from the same patient. RESULTS: Of the total of 50 cases, 26 cases had smears available for the evaluation of BRAF p.V600E immunostaining; positive immunostaining was noted in 16 samples and negative immunostaining was noted in 4 samples, whereas 6 cases were equivocal. Of the 34 cases for which cell blocks were available for evaluation, BRAF p.V600E immunostaining was positive in 17 cases, negative in 16 cases, and equivocal in 1 case. The overall sensitivity and specificity of BRAF p.V600E immunostaining on the cell block preparation was 94.4% and 100%, respectively, whereas for the smears it was 80% and 63.6%, respectively. CONCLUSIONS: BRAF p.V600E immunostaining can be performed reliably on thyroid FNA cell block preparations. However, false-positive results on direct smears limit their utility and therefore need to be interpreted with caution. Cancer Cytopathol 2018;126:406-13. © 2018 American Cancer Society.
引用
- Smith AL, Williams MD, Stewart J, et al. Utility of the BRAF p.V600E immunoperoxidase stain in FNA direct smears and cell block preparations from patients with thyroid carcinoma. Cancer Cytopathol. 2018. PMID: 29579361. doi:10.1002/cncy.21992
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。